Review Article
DOI: https://doi.org/10.70749/ijbr.v3i1.507

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

Nanoparticles in Drug Delivery Systems: Challenges, Innovations, And Surface Modification for Targeted Therapeutics

Tasawar Abbas[1], Fatima Kanwar[2], Hazima Tariq[3], Muhammad Raza Malik[4]

[1]Khwaja Fareed University of Engineering & Information Technology (KFUEIT), Rahim Yar Khan, Punjab, Pakistan.
[2]Bahauddin Zakariya University, Multan, Punjab, Pakistan.
[3]University of Sialkot, Sialkot, Punjab, Pakistan.
[4]University of the Punjab, Lahore, Punjab, Pakistan.

ARTICLE INFO

Keywords

Nanoparticles, Drug Delivery, Biocompatibility, Stimuli-Responsive Nanoparticles, Targeted Drug Delivery, Surface Modification, Controlled Release, Nanomedicine.

Corresponding Author: Tasawar Abbas, Khwaja Fareed University of Engineering & Information Technology (KFUEIT), Rahim Yar Khan, Punjab, Pakistan.
Email: tasawarabbas7668@gmail.com

Declaration

Author's Contributions: All authors equally contributed to the study and approved the final manuscript.
Conflict of Interest: No conflict of interest.
Funding: No funding received by the authors.

Article History

Received: 07-10-2024
Revised: 18-12-2024
Accepted: 04-01-2025

ABSTRACT

Nanoparticles have become a transforming platform in drug delivery systems. Their remarkable advancement over traditional methods builds upon an improvement in bioavailability, stability, and controlled delivery of therapeutic agents. Here, we discuss the broad spectrum of potential in nanoparticle-based drug delivery systems. Challenges, innovations, and the surface modification strategies that affect their clinical translation are discussed. Notwithstanding the potential they present, challenges including biocompatibility, toxicity, stability, and targeting efficiency persist in restricting their extensive utilization. The review emphasizes recent advancements, including stimuli-responsive nanoparticles, which provide controlled drug release in reaction to environmental triggers, as well as targeted drug delivery, which facilitates the selective accumulation of therapeutic agents at designated sites of disease. Besides, surface modification techniques, such as PEGylation, ligand conjugation, and charge modulation, have been highly promising in improving the stability of nanoparticles, reducing immunogenicity, and enhancing cellular uptake. The future drug delivery systems that are based on nanoparticles will address these challenges through new innovations in nanoparticle design to effect more targeted and effective treatments. While research advances, nanoparticle-based systems are likely to bring revolution in personalized medicine, tailoring medical therapy for different diseases with minimal side effects and better patient outcomes.

INTRODUCTION

Today, nanoparticles (NPs) are the primary research area of the present day for drug delivery systems because these particles can be used to enhance solubility, bioavailability, and controlled release of therapeutic agents. Their special physicochemical properties, such as nanoscale dimension ranging from 1 to 100 nm, a large surface area, and an ability to incorporate or adsorb a wide variety of hydrophobic and hydrophilic drugs, make NPs excellent candidates for DDSs [1]. Nanoparticles can also be engineered to modify their surface properties, which will allow for specific interactions with biological targets. Changes in size, shape, surface charge, and composition can be made to match the conditions required by specific biological targets to deliver pharmaceuticals directly to diseased tissues or cells, thus reducing unwanted off-target effects and increasing therapeutic efficiency [2]. Nanoparticles also protect drugs from enzymatic degradation or premature release, which further enhances the pharmacokinetics and pharmacodynamics of the drug. Therefore, nanoparticles have become an important tool in addressing many limitations of conventional drug delivery systems [3].

Even though promises are full of nanoparticle-based drug delivery systems, several significant difficulties are present that hinder the clinical translation. The major issues relate to the biocompatibility and toxicity of nanoparticles. The size and surface chemistry of such

nanoparticles are critical in determining interactions with a biological system, potentially leading to immune system activation, cytotoxicity, or unintended accumulation in organs like the liver and spleen [4]. The stability of nanoparticles in biological environments is another critical issue. Nanoparticles can undergo degradation, aggregation, or alteration in their surface properties, leading to a loss of drug encapsulation efficiency or a reduction in targeting ability [5]. Controlled release of the drug at the target site remains a significant challenge as well, as most nanoparticles do not exhibit the desired release profiles in vivo, which can lead to premature drug release or insufficient drug delivery [6]. Moreover, scalability and reproducibility of nanoparticle synthesis methods remain problematic, as large-scale production of nanoparticles with consistent size, shape, and surface characteristics is complex and costly [7]. Finally, the regulatory hurdles for nanoparticles, including safety and toxicity assessments, remain a critical concern for their clinical implementation [8].

Recent advancements in nanoparticle design have focused on improving the efficiency and precision of drug delivery. Innovations include the development of targeted drug delivery systems that exploit the unique characteristics of certain diseases, such as tumors or infections. For instance, ligand-targeted nanoparticles have been designed to bind specifically to receptors that are overexpressed on the surface of cancer cells, enabling selective delivery of chemotherapy agents to the tumor site while minimizing damage to healthy tissues [9]. Another exciting innovation is the use of stimuli-responsive nanoparticles, which release their payload in response to specific environmental triggers, such as changes in pH, temperature, or the presence of specific enzymes. These systems provide enhanced control over drug release, ensuring that drugs are released at the target site in a controlled manner[10]. Polymeric nanoparticles, liposomes, dendrimers, and nanostructured lipid carriers are some examples of nanocarriers that have been developed to offer controlled and sustained release profiles for a variety of therapeutic agents [11]. These innovations hold great promise in addressing many of the limitations associated with traditional DDS and have paved the way for the development of more effective and safer therapeutic strategies [12].

Surface Modification Strategies for Enhanced Drug Delivery

Surface modification of nanoparticles is a crucial strategy to improve their therapeutic efficacy, targeting specificity, and biocompatibility. One of the most commonly employed approaches is the conjugation of targeting ligands (e.g., antibodies, peptides, or small molecules) to the nanoparticle surface. These ligands can bind to specific receptors or antigens present on target cells, such as those found in tumors or inflammatory sites, thereby increasing the accumulation of the drug at the intended location and reducing off-target effects [13]. **Polyethylene glycol (PEG)**ylation is another widely used surface modification technique, which involves the attachment of PEG chains to the nanoparticle surface. PEGylation enhances the stability of nanoparticles by preventing their aggregation and reducing their recognition and clearance by the immune system, thus extending their circulation time in the bloodstream [14]. In addition to passive targeting, active targeting strategies also involve the modification of nanoparticles with specific molecules that can bind to cell surface receptors that are overexpressed on diseased tissues. For example, folate or transferrin can be used to target folate receptors or transferrin receptors, which are commonly overexpressed on cancer cells[15]. These surface modifications significantly improve the targeting efficiency, therapeutic index, and overall clinical outcomes of nanoparticle-based DDS [16].

The field of nanoparticle-based drug delivery is evolving rapidly, with ongoing research focused on addressing the existing challenges and further refining the technology [17]. Future research is expected to explore combination therapies that use nanoparticles to deliver multiple drugs simultaneously, either for synergistic effects or to overcome drug resistance mechanisms [18]. Moreover, advancements in personalized medicine may lead to the development of nanoparticles specifically tailored to an individual's genetic profile, enabling highly personalized therapeutic approaches [19]. Additionally, the integration of diagnostic imaging agents within drug-loaded nanoparticles could allow for real-time monitoring of drug delivery, enhancing treatment efficacy and patient outcomes [20]. While substantial progress has been made, more work is needed to standardize the methods for nanoparticle synthesis, characterize their interactions with biological systems, and ensure that they meet the regulatory standards required for clinical approval [21]. In conclusion, nanoparticles hold great potential for revolutionizing drug delivery systems, and with continued innovation and addressing current challenges, they will likely play a pivotal role in the future of medicine [22].

RESEARCH OBJECTIVES

The main research objectives are;

- To review the challenges limiting the clinical application of nanoparticle-based drug delivery systems, including biocompatibility, stability, and targeting efficiency.
- To examine recent innovations in nanoparticle design and surface modifications that improve drug targeting and controlled release.

- To assess the impact of surface modification strategies on enhancing the therapeutic potential and reducing side effects of nanoparticle drug delivery systems.

Problem Statement

Despite the significant potential of nanoparticle-based Despite their significant abilities, drug delivery systems based on nanoparticles have not gone very far over the last years in overcoming most of the very important challenges remaining as barriers to their widespread application in the clinic. Some of the common problems include lack of adequate biocompatibility, possible toxicity, stability in biological environments, and also problems in attaining controlled and targeted drug delivery. There is no standard procedure for the synthesis and characterization of nanoparticles. In addition, the problem of irregular drug release profiles is also one of the major challenges faced by these systems during the transition from the laboratory environment to practical clinical application. Despite much progress made in designing and surface modifying nanoparticles, solutions are not generally applicable, so further research is needed to solve these problems and make nanoparticle-based drug delivery systems more effective therapeutically.

Significant of the study

This study is important because it will improve the understanding and development of nanoparticle-based drug delivery systems, which can significantly enhance the efficacy and safety of therapeutic interventions. This study will help identify critical areas for improvement by examining the current challenges, innovations, and surface modification strategies of nanoparticle drug delivery, thereby identifying promising solutions that may lead to more targeted, efficient, and safer treatments for a range of diseases, particularly cancer and chronic conditions. The study provides key inputs into the major aspects of the nanoparticle design, especially biocompatibility, stability, and controlled release, aspects extremely important to counter the challenges against translation to the clinic for these highly sophisticated drug delivery systems.

LITERATURE REVIEW

Nanoparticles as Drug Delivery Systems

Nanoparticles have gained significant attention in drug delivery research due to unique characteristics that improve solubility, bioavailability, and controlled release of therapeutic agents. Nanoparticles are very small particles, ranging between 1 and 100 nanometers, and possess a very high surface area. This allows for a relatively large payload. The smaller the size of the particles, the easier it is for them to penetrate tissue as opposed to larger size [23]. Nanoparticles may be engineered with numerous materials such as lipids, polymers, or inorganic compounds to deliver hydrophobic and hydrophilic drugs, whichever may be required by the real needs of the therapies [24]. For example, lipid-based nanoparticles such as liposomes improve the bioavailability of poorly water-soluble drugs, whereas polymeric nanoparticles can provide a controlled release profile that extends the activity of a drug over a period of time [25]. The ability of nanoparticles to protect drugs from degradation, improve drug solubility, and enable sustained or controlled release has made them an exciting tool that can overcome several limitations associated with conventional drug delivery methods, which include poor bioavailability, rapid clearance, and lack of selectivity [26, 27].

Challenges in Nanoparticle-Based Drug Delivery Systems

Although very promising, the successful implementation of nanoparticles in a clinical context faces several barriers. One key concern is that of biocompatibility and toxicity. Since nanoparticles are foreign particles, their contact with biological systems triggers adverse responses like immune activation, inflammation, or cellular toxicity [28]. The surface chemistry, size, and shape of nanoparticles can influence their interactions with the body's immune system, leading to rapid clearance or unwanted accumulation in organs such as the liver, spleen, or lungs [29]. In a study by [30], they observed that the size of nanoparticles significantly affects their uptake by the immune system and subsequent distribution within the body [31]. Furthermore, the stability of nanoparticles in biological environments is another challenge. Nanoparticles may undergo changes in size, shape, or surface properties in response to the physiological conditions, leading to aggregation or degradation of the drug-loaded nanoparticles. This instability can result in a loss of drug encapsulation and a failure to achieve the desired therapeutic effect [23, 32].

Another significant issue is the controlled release of drugs from nanoparticles. For many drugs, particularly those used in cancer or chronic diseases, it is essential that the drug be released at the site of action in a controlled, sustained manner [33]. However, in practice, many nanoparticle formulations do not exhibit optimal release profiles, often leading to premature drug release, inadequate delivery to target cells, or toxic levels of drug accumulation [34]. Research by [35]highlighted the challenge of achieving stable drug encapsulation and controlled release in liposomal formulations, particularly under in vivo conditions [36]. Finally, the scalability and reproducibility of nanoparticle synthesis methods remains an ongoing challenge. Producing nanoparticles at a large scale with consistent size, shape, and surface characteristics is complex, costly, and prone to batch-to-batch variability [37].

Innovations in Nanoparticle Design

Innovations in nanoparticle design have brought up more sophisticated drug delivery systems to meet the needs of these challenges. Stimuli responsive nanocarriers are one of the most promising developments. These nanoparticles can be responsive to specific environmental stimuli, for example, changes in pH, temperature, or enzyme activity. For instance, pH-sensitive nanoparticles are very useful in cancer therapy, because the tumor microenvironment is more acidic compared to normal tissues. Designing nanoparticles that respond to this acidic environment can preferentially release drugs at the tumor site, thus reducing systemic toxicity [38]. A study by [39] demonstrated that pH-sensitive nanoparticles could release chemotherapy agents selectively in acidic tumor environments, significantly improving therapeutic efficacy [11]. Additionally, temperature-sensitive or enzyme-triggered nanoparticles are being explored for various therapeutic applications, including localized drug delivery in conditions like inflammation or infections [40, 41].

Another important advancement in nanoparticle design is targeted drug delivery systems. Targeting nanoparticles to specific tissues or cells provides the primary approach through which the efficacy and side effects of the therapy could be improved. The surface modification of particles with specific targeting ligands, for instance, antibodies, peptides, or small molecules, helps guide the nanoparticles to overexpressed receptors on the surface of the targeted cells. Such cells may include cancerous cells or inflammatory cells [42]. For example, nanoparticles modified with folic acid can selectively target cancer cells that overexpress folate receptors, while nanoparticles coated with transferrin can target tumor cells with high transferrin receptor expression [43]. Research by [44] provided evidence that folate-targeted nanoparticles were more effectively delivered to cancer cells, enhancing the therapeutic efficacy of the drug payload [45].

Surface modification is one of the most important strategies to enhance targeting efficiency, stability, and biocompatibility of nanoparticles. One of the widely used surface modification techniques is PEGylation. PEGylation is a method in which PEG molecules are attached to the surface of the nanoparticles. The attachment of PEG molecules on the surface of nanoparticles prevents nanoparticle aggregation, reduces immune recognition, and therefore prolongs the circulation time of nanoparticles, improving their bioavailability [46]. This modification helps nanoparticles evade clearance by the reticuloendothelial system (RES), which is responsible for the rapid removal of foreign particles from the bloodstream. A study by [47] demonstrated that PEGylated nanoparticles had increased systemic circulation time and better drug delivery to the tumor site [48].

In addition to PEGylation, the conjugation of specific ligands to the nanoparticle surface enhances the selective targeting of nanoparticles to diseased tissues. These ligands can be antibodies, peptides, or small molecules that bind to receptors overexpressed on the surface of target cells [49]. For example, antibody-conjugated nanoparticles have shown promise in delivering chemotherapeutic drugs directly to cancer cells, increasing the efficacy of the drug while minimizing side effects [50]. Furthermore, nanoparticles can be modified with charged groups to improve their interaction with the negatively charged cell membranes, increasing cellular uptake [51]. A study by [52] found that surface charge played a significant role in nanoparticle cellular uptake and biodistribution [53].

Other surface modification strategies include the attachment of proteins, carbohydrates, or cell-penetrating peptides to facilitate intracellular drug delivery. For example, the use of cell-penetrating peptides (CPPs) can promote the entry of nanoparticles into cells and enhance the release of encapsulated drugs from the nanoparticles within the intracellular environment [54]. These surface modifications significantly improve the performance of nanoparticle-based drug delivery systems, enabling more precise targeting, reduced toxicity, and better therapeutic outcomes [55].

Nanoparticle-based drug delivery systems have been widely studied for various therapeutic applications, including cancer, gene therapy, and the treatment of chronic diseases. In cancer therapy, nanoparticles can improve the delivery of chemotherapeutic agents, overcome multidrug resistance, and provide sustained drug release to minimize the side effects of conventional therapies [56]. Liposomal formulations, for instance, have been successfully used to encapsulate chemotherapeutic drugs, such as doxorubicin, and deliver them directly to tumor sites, improving drug accumulation and reducing systemic toxicity [57]. Similarly, nanoparticles have been explored for gene delivery, where they can protect nucleic acids (such as DNA or RNA) from degradation and deliver them efficiently to target cells for gene therapy [58]. Additionally, nanoparticle-based systems have shown promise in the treatment of chronic diseases such as diabetes, arthritis, and cardiovascular conditions, where long-term drug release and sustained therapeutic effects are essential [59].

Challenges Limiting the Clinical Application of Nanoparticle-Based Drug Delivery Systems

Biocompatibility and Toxicity Issues

One of the primary concerns in the clinical translation of nanoparticle-based drug delivery systems is biocompatibility and toxicity. Nanoparticles are engineered to interact with biological systems at the cellular level, which can sometimes lead to unintended

effects such as immune response activation, inflammation, or cytotoxicity. The surface chemistry, size, and shape of nanoparticles are critical factors that determine their interaction with cells and the immune system. For example, small-sized nanoparticles (under 10 nm) tend to accumulate in organs like the liver and spleen due to the body's natural filtration mechanisms, potentially leading to toxicity [60]. Additionally, studies have shown that certain nanoparticle formulations can trigger allergic reactions or cytotoxic effects, limiting their application for long-term therapy [61]. Moreover, nanoparticles that lack proper surface modification can be rapidly cleared from circulation, reducing their bioavailability and therapeutic efficacy [62].

Stability and Aggregation Challenges

The stability of nanoparticles in biological environments is another significant challenge. Nanoparticles are inherently unstable in the bloodstream, where they are subject to complex interactions with plasma proteins, ions, and other biological molecules. This instability can result in aggregation or size changes that compromise the drug release profile and therapeutic efficacy. For instance, lipid-based nanoparticles can undergo lipid oxidation or hydrolysis in the blood, leading to instability and premature drug release [63]. Furthermore, the aggregation of nanoparticles can increase their size, causing them to be cleared by the reticuloendothelial system (RES) before reaching the target site [15, 64]. Therefore, controlling the physicochemical properties of nanoparticles, such as size, surface charge, and functionalization, is crucial to ensuring stability in vivo [65].

Controlled Release and Targeting Efficiency

A major hurdle in nanoparticle-based drug delivery systems is achieving precise control over drug release and ensuring efficient targeting to diseased tissues. Many nanoparticle formulations fail to deliver the drug precisely at the target site, resulting in either premature drug release or insufficient drug exposure at the target tissue [66]. Moreover, achieving selective drug release at the target site is challenging, as the nanoparticle must be able to overcome the biological barriers, such as the blood-brain barrier (BBB) in the case of central nervous system diseases, or the extracellular matrix (ECM) in tumors [67] . For nanoparticles to be effective, they must be able to precisely target cancerous or diseased cells while avoiding healthy tissues, reducing the overall toxicity of the therapy. However, despite significant progress, efficient targeting remains one of the biggest challenges in the field [68].

Innovations in Nanoparticle Design for Drug Delivery

Stimuli-Responsive Nanoparticles

In recent years, stimuli-responsive nanoparticles have been developed to address the challenges of controlled drug release. These nanoparticles are engineered to release their payload in response to specific environmental triggers, such as changes in pH, temperature, or the presence of specific enzymes. For example, in cancer therapy, the tumor microenvironment tends to be more acidic than normal tissues, providing an ideal target for pH-sensitive nanoparticles. These nanoparticles release their drug payload only when they encounter the acidic environment of the tumor, reducing the risk of drug leakage in healthy tissues [69]. Researchers like [70] have demonstrated that pH-sensitive nanoparticles can achieve selective drug release at the tumor site, improving therapeutic outcomes and minimizing off-target toxicity [71]. Other types of stimuli-responsive nanoparticles include those that respond to thermal changes or ultrasound exposure, offering more versatile drug delivery systems for a range of clinical applications [72] .

Targeted Drug Delivery Systems

Targeted drug delivery remains a cornerstone of nanoparticle design, particularly for applications in oncology. Recent innovations have focused on the modification of nanoparticles' surfaces with specific ligands or molecules that can interact with overexpressed receptors on the surface of cancer cells or other diseased tissues. For instance, folate receptor-targeted nanoparticles have been shown to selectively deliver drugs to cancer cells that overexpress the folate receptor, enhancing the drug's efficacy while minimizing side effects [73]. Additionally, antibody-conjugated nanoparticles offer another approach for targeted delivery by using antibodies that bind to specific tumor-associated antigens. Transferrin receptor-targeted nanoparticles are another promising strategy, especially for glioblastoma, a type of brain cancer, due to the overexpression of transferrin receptors in tumor cells [74]. These targeted strategies ensure that the drug is delivered specifically to the disease site, improving treatment outcomes and reducing systemic toxicity.

Polymeric and Hybrid Nanoparticles

Polymeric nanoparticles have shown considerable promise for controlled drug delivery and sustained release due to their biocompatibility, biodegradability, and ease of modification. Polymeric nanoparticles, such as PLGA (poly (lactic-co-glycolic acid)), are frequently used in controlled-release formulations, allowing for long-term drug delivery without the need for repeated administration [75]. Furthermore, hybrid nanoparticles that combine different types of materials, such as organic and inorganic components, have emerged as effective drug delivery systems. These hybrid systems combine the flexibility and biodegradability of polymers with the high surface area and stability of inorganic materials, such as silica nanoparticles or gold nanoparticles, to provide targeted and efficient drug delivery while also

improving the therapeutic efficacy of the encapsulated drug [76].

Surface Modification Strategies for Enhanced Drug Delivery

PEGylation for Enhanced Stability

One of the most widely used surface modification techniques is PEGylation, where polyethylene glycol (PEG) chains are attached to the surface of nanoparticles to enhance their biocompatibility and circulation time. PEGylation reduces the immunogenicity of nanoparticles, preventing recognition and clearance by the immune system, which allows nanoparticles to circulate for longer periods, thereby increasing their drug delivery efficiency [77]. A study by [78] demonstrated that PEGylated liposomes could prolong the drug's half-life in circulation, improving tumor accumulation and enhancing therapeutic efficacy [79]. However, it is important to balance the PEG length to ensure optimal drug delivery and to avoid "PEGylation-induced immunogenicity" that might arise from prolonged exposure to PEG chains [80].

Active Targeting with Ligand Conjugation

Another promising strategy for enhancing targeted drug delivery is the use of ligand conjugation to modify the surface of nanoparticles. Ligands, such as antibodies, peptides, or small molecules, are used to bind to specific receptors or antigens on the surface of target cells, allowing nanoparticles to selectively accumulate in diseased tissues. For example, HER2-targeted nanoparticles have been proven to deliver anticancer agents into breast cancer cells that overexpress the HER2 receptor, and thus, this improves the therapeutic outcomes of patients with HER2-positive breast cancer [81]. Additionally, folate, transferrin, and antibody-based targeting are commonly used for active targeting in various cancers, where these receptors are overexpressed on the surface of tumor cells. This active targeting approach enhances the selectivity of drug delivery, ensuring that therapeutic agents reach the target site without affecting healthy tissues [82].

Charge Modification and Cellular Uptake

Surface charge modulation is another approach adapted for better uptake of nanoparticles in cells. The charge at the surface of nanoparticles may affect how they interact with cell membranes, which consequently influences the extent to which endocytosis and drug delivery takes place within the cell. Therefore, cationic nanoparticles are taken up more efficiently by negatively charged cell membranes and are preferred for gene delivery application [83]. However, the positive charge can also lead to toxicity and unwanted aggregation. Therefore, charge modulation through the incorporation of neutral or anionic functional groups can help balance the uptake and reduce potential toxic effects while improving the therapeutic delivery of the drug [84, 85].

CONCLUSION

In conclusion, nanoparticle-based drug delivery systems hold much promise for the transformation of modern therapeutics by overcoming limitations in conventional drug delivery methods. They offer improved bioavailability, targeted drug delivery, and controlled, sustained release to make them particularly appealing for applications in cancer therapy, gene therapy, and the treatment of chronic diseases. However, as discussed in detail in this review, several challenges remain, including biocompatibility, toxicity, stability, and controlled release mechanisms, which prevent their widespread clinical application. These issues must be addressed to fully realize the clinical potential of nanoparticles in drug delivery.

In relation to the first research objective, this review has identified different challenges that still limit the effective clinical use of nanoparticle-based drug delivery systems. Toxicity with certain nanoparticles and complex interactions with the immune system can make their therapeutic use complicated. Additionally, the stability of nanoparticles in biological environments is a significant challenge since these systems are often prone to undesired aggregation or degradation, which affects the drug release profiles. Further research into optimizing nanoparticle design and surface modifications for enhanced biocompatibility and stability in vivo will be needed to overcome these issues. As we discussed, although there is significant progress, translating nanoparticle drug delivery from the laboratory to the clinic is still an enormous challenge that needs to be overcome.

The second research objective, focusing on the exploration of innovation in the design of nanoparticles, was also largely discussed in this review. The most impressive category of responsive nanoparticles is those that, in theory, can deliver drugs with higher precision using environmental stimuli like pH and temperature to release them. In addition, ligand-modified targeted drug delivery systems in guiding nanoparticles to specific tissues or cells have brought forth great promises of reducing the side effects due to off-target and increasing the efficacy of therapeutics. All these innovations opened up new pathways to enhance the delivery of drugs to tumors or inflammatory sites where they are required most and also to reduce the systemic toxicity due to drugs. Surface modification strategies were addressed as the third research objective which formed the culmination of the review. Modifications used in this end comprise PEGylation, which had been widely utilized to elongate circulation times and reduce immunological recognition and ligand conjugation, facilitating selective targeting to diseased tissue. Additionally, alteration of charge at the nanoscale might be used in enhancing cellular uptake of nanoparticles which increases their efficacies in cell-specific delivery.

These surface modification strategies are critical for improving the selectivity and efficacy of nanoparticle-based therapies, ensuring that drugs can be delivered in a more precise manner with fewer side effects.

In summary, recent innovations and surface modification strategies in nanoparticle design are excellent approaches to overcoming these barriers. The next phase of research must refine these systems, optimize their performance, and ensure safe and efficient translation into clinical use. By addressing challenges in biocompatibility, stability, and targeted delivery, nanoparticle-based drug delivery systems are poised to revolutionize therapeutic interventions and improve patient outcomes.

Future Implication

Nanoparticle-based drug delivery systems are the future and are promising with significant transformation of the personalized medicine and targeted therapies landscape. Research into smarter and more efficient nanoparticles is in the process, allowing precise targeting of diseases, such as cancer, neurological disorders, and chronic diseases, without the risk of many side effects. The potential innovations in stimuli-responsive and biodegradable nanoparticles, with enhanced surface modifications, will open up dynamic, on-demand drug release, thereby enabling more effective treatment regimens that are tailored to the individual patient. Additionally, because nanoparticles are increasingly being designed for multifunctional purposes, such as simultaneous drug delivery and diagnostic imaging (theranostics), they have immense potential for revolutionizing not only treatment but also disease monitoring and early detection. Challenges associated with clinical safety, scale up of production and regulatory approvals to unlock full nanoparticle-based drug delivery system real-world application will be essential for achieving approval.

REFERENCES

1. Juillerat-Jeanneret, L., & Schmitt, F. (2006). Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail. *Medicinal Research Reviews*, *27*(4), 574-590. https://doi.org/10.1002/med.20086
2. Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., Shi, J., Huang, Y., Guo, W., Peng, S., Zhou, W., & Gao, H. (2023). Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. *Chinese Chemical Letters*, *34*(2), 107518. https://doi.org/10.1016/j.cclet.2022.05.032
3. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2020). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*, *20*(2), 101-124. https://doi.org/10.1038/s41573-020-0090-8
4. Jiang, W., Kim, B. Y., Rutka, J. T., & Chan, W. C. (2007). Advances and challenges of nanotechnology-based drug delivery systems. *Expert Opinion on Drug Delivery*, *4*(6), 621-633. https://doi.org/10.1517/17425247.4.6.621
5. Afzal, O., Altamimi, A. S., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., & Kazmi, I. (2022). Nanoparticles in drug delivery: From history to therapeutic applications. *Nanomaterials*, *12*(24), 4494. https://doi.org/10.3390/nano12244494
6. Vasir, J., Reddy, M., & Labhasetwar, V. (2005). Nanosystems in drug targeting: Opportunities and challenges. *Current Nanoscience*, *1*(1), 47-64. https://doi.org/10.2174/1573413052953110
7. Reddy, K. T., & Reddy, A. S. (2025). Recent breakthroughs in drug delivery systems for targeted cancer therapy: An overview. *Cellular, Molecular and Biomedical Reports*, *5*(1), 13-27. https://doi.org/10.55705/cmbr.2025.456494.1246
8. Kumar, A., Zhang, X., & Liang, X. (2013). Gold nanoparticles: Emerging paradigm for targeted drug delivery system. *Biotechnology Advances*, *31*(5), 593-606. https://doi.org/10.1016/j.biotechadv.2012.10.002
9. Chandrakala, V., Aruna, V., & Angajala, G. (2022). Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems. *Emergent Materials*, *5*(6), 1593-1615. https://doi.org/10.1007/s42247-021-00335-x
10. Mirza, Z., & Karim, S. (2021). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Seminars in Cancer Biology*, *69*, 226-237. https://doi.org/10.1016/j.semcancer.2019.10.020
11. Yih, T., & Al-Fandi, M. (2006). Engineered nanoparticles as precise drug delivery systems. *Journal of Cellular Biochemistry*, *97*(6), 1184-1190. https://doi.org/10.1002/jcb.20796

12. Sosnik, A., & Augustine, R. (2016). Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. *Advanced Drug Delivery Reviews*, *103*, 105-120. https://doi.org/10.1016/j.addr.2015.12.022
13. Singh, D. (2024). Organelle targeted drug delivery: Key challenges, recent Advancementsand therapeutic implications. *Endocrine, Metabolic & Immune Disorders - Drug Targets*, *24*(13), 1480-1487. https://doi.org/10.2174/0118715303282573240112104035
14. Sur, S., Rathore, A., Dave, V., Reddy, K. R., Chouhan, R. S., & Sadhu, V. (2019). Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. *Nano-Structures & Nano-Objects*, *20*, 100397. https://doi.org/10.1016/j.nanoso.2019.100397
15. Zakaria, M. M., Alzayed, K. S. M., Meashi, A. I., Al Ghamdi, S. A., Almowaled, S. S. S., Alnakhly, A. A., ... & Fadaaq, M. A. (2023). Revolutionizing Drug Delivery: Innovations And Challenges In Nanotechnology. *Journal of Namibian Studies: History Politics Culture*, *38*, 1786-1797.
16. Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology*, *86*(3), 215-223. https://doi.org/10.1016/j.yexmp.2008.12.004
17. Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021). Targeted drug delivery strategies for precision medicines. *Nature Reviews Materials*, *6*(4), 351-370. https://doi.org/10.1038/s41578-020-00269-6
18. Jain, K. K. (2019). An overview of drug delivery systems. *Methods in Molecular Biology*, 1-54. https://doi.org/10.1007/978-1-4939-9798-5_1
19. Paul, W., & Sharma, C. P. (2020). Inorganic nanoparticles for targeted drug delivery. *Biointegration of Medical Implant Materials*, 333-373. https://doi.org/10.1016/b978-0-08-102680-9.00013-5
20. Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2012). Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. *Nanomedicine*, *7*(8), 1253-1271. https://doi.org/10.2217/nnm.12.87
21. Akhtar, A., Andleeb, A., Waris, T. S., Bazzar, M., Moradi, A., Awan, N. R., & Yar, M. (2021). Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. *Journal of Controlled Release*, *330*, 1152-1167. https://doi.org/10.1016/j.jconrel.2020.11.021
22. Kumar Sarella, P. N., Vegi, S., Kumari Vendi, V., Kumar Vipparthi, A., & Valluri, S. (2024). Exploring Aquasomes: A promising frontier in nanotechnology-based drug delivery. *Asian Journal of Pharmaceutical Research*, 153-161. https://doi.org/10.52711/2231-5691.2024.00026
23. Al Tahan, M. A., & Al Tahan, S. (2024). Pioneering advances and innovative applications of Mesoporous carriers for mitochondria-targeted therapeutics. *British Journal of Biomedical Science*, *81*. https://doi.org/10.3389/bjbs.2024.13707
24. Priya, S., Desai, V. M., & Singhvi, G. (2022). Surface modification of lipid-based Nanocarriers: A potential approach to enhance targeted drug delivery. *ACS Omega*, *8*(1), 74-86. https://doi.org/10.1021/acsomega.2c05976
25. Cojocaru, E., Petriș, O. R., & Cojocaru, C. (2024). Nanoparticle-based drug delivery systems in inhaled therapy: Improving respiratory medicine. *Pharmaceuticals*, *17*(8), 1059. https://doi.org/10.3390/ph17081059
26. Faraji, A. H., & Wipf, P. (2009). Nanoparticles in cellular drug delivery. *Bioorganic & Medicinal Chemistry*, *17*(8), 2950-2962. https://doi.org/10.1016/j.bmc.2009.02.043
27. Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L., Nair, M. P., & Verma, H. K. (2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. *Journal of Drug Delivery Science and Technology*, *63*, 102487. https://doi.org/10.1016/j.jddst.2021.102487
28. Shah, S. S., Shaikh, M. N., Khan, M. Y., Alfasane, M. A., Rahman, M. M., & Aziz, M. A. (2021). Present status and future prospects of jute in nanotechnology: A review. *The Chemical Record*, *21*(7), 1631-1665. https://doi.org/10.1002/tcr.202100135
29. Kakde, D., Jain, D., Shrivastava, V., Kakde, R., & Patil, A. T. (2011). Cancer therapeutics-opportunities, challenges and advances in drug delivery. *Journal of Applied Pharmaceutical Science*, (Issue), 01-10.

https://japsonline.com/abstract.php?article_id=252

30. Babu, A., Templeton, A. K., Munshi, A., & Ramesh, R. (2013). Nanoparticle-based drug delivery for therapy of lung cancer: Progress and challenges. *Journal of Nanomaterials*, *2013*(1). https://doi.org/10.1155/2013/863951
31. Watermann, A., & Brieger, J. (2017). Mesoporous silica nanoparticles as drug delivery vehicles in cancer. *Nanomaterials*, *7*(7), 189. https://doi.org/10.3390/nano7070189
32. Naser, I. H., Zaid, M., Ali, E., Jabar, H. I., Mustafa, A. N., Alubiady, M. H., Ramadan, M. F., Muzammil, K., Khalaf, R. M., Jalal, S. S., Alawadi, A. H., & Alsalamy, A. (2023). Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma. *Naunyn-Schmiedeberg's Archives of Pharmacology*, *397*(6), 3747-3770. https://doi.org/10.1007/s00210-023-02885-9
33. Parveen, S., Misra, R., & Sahoo, S. K. (2017). Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine in Cancer*, 47-98. https://doi.org/10.1201/b22358-3
34. Harishchandra, V. B. Nanoparticle Applications in Drug Delivery: Progression, Hurdles, and Prospects.
35. Servatan, M., Zarrintaj, P., Mahmodi, G., Kim, S., Ganjali, M. R., Saeb, M. R., & Mozafari, M. (2020). Zeolites in drug delivery: Progress, challenges and opportunities. *Drug Discovery Today*, *25*(4), 642-656. https://doi.org/10.1016/j.drudis.2020.02.005
36. Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023). Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles' Physicochemical Properties on Responses in Biological Systems. *Polymers*, *15*(7), 1596. https://doi.org/10.3390/polym15071596
37. Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019). Ocular Drug Delivery: Present Innovations and Future Challenges. *Journal of Pharmacology and Experimental Therapeutics*, *370*(3), 602–624. https://doi.org/10.1124/jpet.119.256933
38. Chang, D., Gao, Y., Wang, L., Liu, G., Chen, Y., Wang, T., Tao, W., Mei, L., Huang, L., & Zeng, X. (2016). Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy. *Journal of Colloid and Interface Science*, *463*, 279–287. https://doi.org/10.1016/j.jcis.2015.11.001
39. Acharya, B., Behera, A., Behera, S., & Moharana, S. (2024). Recent Advances in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Reproductive Disorders. *ACS Applied Bio Materials*, *7*(3), 1336–1361. https://doi.org/10.1021/acsabm.3c01064
40. Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022). Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review. *ACS Applied Bio Materials*, *5*(3), 971–1012. https://doi.org/10.1021/acsabm.2c00002
41. Alavi, S. E., Alharthi, S., Alavi, S. Z., Raza, A., & Shahmabadi, H. E. (2024). Bioresponsive drug delivery systems. *Drug Discovery Today*, *29*(1), 103849–103849. https://doi.org/10.1016/j.drudis.2023.103849
42. Sonowal, L., & Gautam, S. (2024). Advancements and challenges in carbon nanotube-based drug delivery systems. *Nano-Structures & Nano-Objects*, *38*, 101117. https://doi.org/10.1016/j.nanoso.2024.101117
43. Honmane, S. M., Charde, M. S., Salunkhe, S. S., Choudhari, P. B., & Nangare, S. N. (2022). Polydopamine surface-modified nanocarriers for improved anticancer activity: Current progress and future prospects. *OpenNano*, *7*, 100059. https://doi.org/10.1016/j.onano.2022.100059
44. Gupta, J., & Sharma, G. (2024). Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective. *Drug Delivery and Translational Research*. https://doi.org/10.1007/s13346-024-01684-w
45. Nayak, D., Rathnanand, M., & Tippavajhala, V. K. (2024). Navigating Skin Delivery Horizon: An Innovative Approach in Pioneering Surface Modification of Ultradeformable Vesicles. *AAPS PharmSciTech*, *25*(5). https://doi.org/10.1208/s12249-024-02847-1
46. Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. *Signal Transduction and Targeted Therapy*, *3*(1). https://doi.org/10.1038/s41392-017-0004-3
47. Bala, I., Hariharan, S., & Kumar, M. R. (2004). PLGA Nanoparticles in Drug Delivery: The State of the Art; *Critical Reviews in Therapeutic*

Drug Carrier Systems, *21*(5), 387–422. https://doi.org/10.1615/critrevtherdrugcarriersyst.v21.i5.20

48. Dachani, S. R., Vashi, A., Mundada, A. B., Mundada, P. A., Ravi, S., Rudrangi, S., & Tiwari, R. (2024). "Innovative Polymers in Pharmaceutical Chemistry: Revolutionizing Drug Delivery Systems." *Polymer-Plastics Technology and Materials*, 1–23. https://doi.org/10.1080/25740881.2024.2440531
49. Theivendren, P., Kunjiappan, S., Pavadai, P., Ravi, K., Murugavel, A., Dayalan, A., & Santhana Krishna Kumar, A. (2024). Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy. *ACS Measurement Science Au*. https://doi.org/10.1021/acsmeasuresciau.4c00062
50. Pissuwan, D., Niidome, T., & Cortie, M. B. (2011). The forthcoming applications of gold nanoparticles in drug and gene delivery systems. *Journal of Controlled Release*, *149*(1), 65–71. https://doi.org/10.1016/j.jconrel.2009.12.006
51. Lorscheider, M., Gaudin, A., Nakhlé, J., Veiman, K.-L., Richard, J., & Chassaing, C. (2020). Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. *Therapeutic Delivery*, *12*(1). https://doi.org/10.4155/tde-2020-0079
52. Katz, J. S., Chou, D. K., Christian, T. R., Das, T. K., Patel, M. M., Singh, S. N., & Wen, Y. (2022). Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations. *Journal of Pharmaceutical Sciences*, *111*(4), 919–932. https://doi.org/10.1016/j.xphs.2021.12.002
53. Jyothika, M., Gowda, S. M., Kumar, G. B., Rakshitha, K. B., Srikruthi, K. S., Goudanavar, P., & Naveen, N. R. (2024). Innovative polymer modifications: Unlocking new horizons in drug delivery applications. *Biomedical Materials & Devices*. https://doi.org/10.1007/s44174-024-00258-1
54. Puttasiddaiah, R., Basavegowda, N., Lakshmanagowda, N. K., Raghavendra, V. B., Sagar, N., Sridhar, K., Dikkala, P. K., Bhaswant, M., Baek, K., & Sharma, M. (2025). Emerging nanoparticle-based diagnostics and therapeutics for cancer: Innovations and challenges. *Pharmaceutics*, *17*(1), 70. https://doi.org/10.3390/pharmaceutics17010070
55. Alcantara, K. P., Malabanan, J. W., Vajragupta, O., Rojsitthisak, P., & Rojsitthisak, P. (2024). A promising strategy of surface-modified nanoparticles targeting CXCR4 for precision cancer therapy. *Journal of Drug Targeting*, *32*(6), 587-605. https://doi.org/10.1080/1061186x.2024.2345235
56. Hua, S., De Matos, M. B., Metselaar, J. M., & Storm, G. (2018). Current trends and challenges in the clinical translation of Nanoparticulate Nanomedicines: Pathways for translational development and commercialization. *Frontiers in Pharmacology*, *9*. https://doi.org/10.3389/fphar.2018.00790
57. Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014). Nanomaterials for Theranostics: Recent advances and future challenges. *Chemical Reviews*, *115*(1), 327-394. https://doi.org/10.1021/cr300213b
58. Kaymaz, S. V., Nobar, H. M., Sarıgül, H., Soylukan, C., Akyüz, L., & Yüce, M. (2023). Nanomaterial surface modification toolkit: Principles, components, recipes, and applications. *Advances in Colloid and Interface Science*, *322*, 103035. https://doi.org/10.1016/j.cis.2023.103035
59. Hamdy, N. M., Basalious, E. B., El-Sisi, M. G., Nasr, M., Kabel, A. M., Nossier, E. S., & Abadi, A. H. (2024). Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: A step-toward personalized medicine. *Current Medical Research and Opinion*, *40*(11), 1943-1961. https://doi.org/10.1080/03007995.2024.2416985
60. Comanescu, C. (2023). Recent advances in surface Functionalization of magnetic nanoparticles. *Coatings*, *13*(10), 1772. https://doi.org/10.3390/coatings13101772
61. Desai, N. (2012). Challenges in development of nanoparticle-based therapeutics. *The AAPS Journal*, *14*(2), 282-295. https://doi.org/10.1208/s12248-012-9339-4
62. Khawas, S. (2024). Innovations in Nanocarrier technology for targeted therapeutics: A comprehensive review. *Revista Electronica de Veterinaria*, 1076-1089. https://doi.org/10.69980/redvet.v25i1.780
63. Khot, S., Krishnaveni, A., Gharat, S., Momin, M., Bhavsar, C., & Omri, A. (2024).

Innovative drug delivery strategies for targeting glioblastoma: Overcoming the challenges of the tumor microenvironment. *Expert Opinion on Drug Delivery*, *21*(12), 1837-1857. https://doi.org/10.1080/17425247.2024.2429702

64. Esmaeili, S. (2023). Innovations in Surface Modification Techniques: Advancing Hydrophilic\textit {LiYF $ _ {4} $: Yb, Er, Tm} Upconversion Nanoparticles and Their Applications. https://doi.org/10.1021/acsanm.2c03681.s002
65. Javanmard, Z., Pourhajibagher, M., & Bahador, A. (2024). Advancing anti-biofilm strategies: Innovations to combat biofilm-related challenges and enhance efficacy. *Journal of Basic Microbiology*, *64*(12). https://doi.org/10.1002/jobm.202400271
66. Sechi, M., Sanna, V., & Pala, N. (2014). Targeted therapy using nanotechnology: Focus on cancer. *International Journal of Nanomedicine*, 467. https://doi.org/10.2147/ijn.s36654
67. Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q., Pecho, R. D., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M. J., Amajd, A., Abo-Zaid, M. A., Castillo-Acobo, R. Y., Ismail, A. H., Amin, A. H., & Akhavan-Sigari, R. (2023). Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation. *Molecular Cancer*, *22*(1). https://doi.org/10.1186/s12943-023-01865-0
68. Dong, C., Yu, X., Jin, K., & Qian, J. (2023). Overcoming brain barriers through surface-functionalized liposomes for glioblastoma therapy; Current status, challenges and future perspective. *Nanomedicine*, *18*(30), 2161-2184. https://doi.org/10.2217/nnm-2023-0172
69. Parsai, H. (2024). The Role of Nanotechnology in Drug Delivery: Innovations in Molecular Therapeutics. *Multidisciplinary Journal of Molecular Biology and Biochemistry*, *1*(1), 49-56. https://www.researchcorridor.org/index.php/mjmbb/article/view/127
70. Vargas, R., Lizano-Barrantes, C., Romero, M., Valencia-Clua, K., Narváez-Narváez, D. A., Suñé-Negre, J. M., Pérez-Lozano, P., García-Montoya, E., Martinez-Martinez, N., Hernández-Munain, C., Suñé, C., & Suñé-Pou, M. (2024). The piper at the gates of brain: A systematic review of surface modification strategies on lipid nanoparticles to overcome the blood-brain-Barrier. *International Journal of Pharmaceutics*, *665*, 124686. https://doi.org/10.1016/j.ijpharm.2024.124686
71. Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. *Blood Cancer Journal*, *11*(4). https://doi.org/10.1038/s41408-021-00459-7
72. Vishvakarma, P., Kumari, R., Vanmathi, S. M., Devi Korni, R., Bhattacharya, V., E. Jesudasan, R., & Mandal, S. (2023). Oral delivery of peptide and protein therapeutics: Challenges and strategies. *Journal of Experimental Zoology India*, *26*(2). https://doi.org/10.51470/jez.2023.26.2.2301
73. Sawant, R. R., & Torchilin, V. P. (2012). Challenges in development of targeted liposomal therapeutics. *The AAPS Journal*, *14*(2), 303-315. https://doi.org/10.1208/s12248-012-9330-0
74. Ejeta, B. M., Das, M. K., & Das, S. (2024). Recent Advances in Paclitaxel Drug Delivery: Challenges, Innovations, and Future Directions. *Journal of Angiotherapy*, *8*(8), 1-13. https://doi.org/10.25163/angiotherapy.889867
75. Pandya, S. R., Singh, H., Desimone, M. F., Singh, J., George, N., & Jasani, S. (2024). Circumventing challenges in mitochondrial targeting for cancer treatment: Leveraging nanoplatforms for effective solutions. *Materials Advances*, *5*(2), 409-431. https://doi.org/10.1039/d3ma00629h
76. Iravani, S., & Varma, R. S. (2021). MXenes for cancer therapy and diagnosis: Recent advances and current challenges. *ACS Biomaterials Science & Engineering*, *7*(6), 1900-1913. https://doi.org/10.1021/acsbiomaterials.0c01763
77. Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019). Current trends and challenges in cancer management and therapy using designer nanomaterials. *Nano Convergence*, *6*(1). https://doi.org/10.1186/s40580-019-0193-2
78. Farokhi, S., Razavi, Z., Mavaei, M., Shadab, A., Afkhami, H., & Sardarabadi, H. (2024). New perspectives on arteriosclerosis treatment using nanoparticles and mesenchymal stem cells. *Discover Applied Sciences*, *6*(8). https://doi.org/10.1007/s42452-024-06113-8

79. Brown, K. A., Melby, J. A., Roberts, D. S., & Ge, Y. (2020). Top-down proteomics: Challenges, innovations, and applications in basic and clinical research. *Expert Review of Proteomics*, *17*(10), 719-733. https://doi.org/10.1080/14789450.2020.1855982

80. Agrawal, S. S., Baliga, V., & Londhe, V. Y. (2024). Liposomal formulations: A recent update. *Pharmaceutics*, *17*(1), 36. https://doi.org/10.3390/pharmaceutics17010036

81. Kumari, S., Raj, S., Babu, M. A., Bhatti, G. K., & Bhatti, J. S. (2023). Antibody-drug conjugates in cancer therapy: Innovations, challenges, and future directions. *Archives of Pharmacal Research*, *47*(1), 40-65. https://doi.org/10.1007/s12272-023-01479-6

82. Anwarkhan, S., Koilpillai, J., & Narayanasamy, D. (2024). Utilizing multifaceted approaches to target drug delivery in the brain: From nanoparticles to biological therapies. *Cureus*. https://doi.org/10.7759/cureus.68419

83. Rajan, S. S., Chandran, R., & Abrahamse, H. (2024). Overcoming challenges in cancer treatment: Nano-enabled photodynamic therapy as a viable solution. *WIREs Nanomedicine and Nanobiotechnology*, *16*(1). https://doi.org/10.1002/wnan.1942

84. Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023). Smart nanomaterials in cancer Theranostics: Challenges and opportunities. *ACS Omega*, *8*(16), 14290-14320. https://doi.org/10.1021/acsomega.2c07840

85. Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H., Severino, P., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024). Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. *Acta Biomaterialia*, *180*, 1-17. https://doi.org/10.1016/j.actbio.2024.04.010